RPRX: Agreed. Also, the presentation, tho boring, reinforced the notion that Pro is going to be a slam dunk in my estimation. rfj has not been overly giddy on this company.
I'm hoping that Andro gets thru the FDA more easily than currently surmised; it represents a nice upside, tho not necessary for the valuation that David and some of us foresee.
I added even more the day before, even tho it dropped somewhat from that purchase price.
News 
Market Data 
Discover 
